FDA announces new safety recommendations for high-dose simvastatin June 2011
Was this earlier research not good enough to write a stroke protocol on it? OR didn't you know about it? Incompetence for either answer.
tested in rats from 2003
http://oc1dean.blogspot.com/2011/09/statins-induce-angiogenesis.html
http://oc1dean.blogspot.com/2013/02/simvastatin-attenuates-stroke-induced.html
Or,
http://oc1dean.blogspot.com/2012/10/simvastatin-attenuates-axonal-injury.html
tested in humans, March, 2011
http://www.medwirenews.com/39/91658/Stroke/Acute_statin_therapy_improves_survival_after_ischemic_stroke.html
http://stroke.ahajournals.org/content/48/11/2922?etoc=
See related article, p 3057
The
pivotal SPARCL trial (Stroke Prevention by Aggressive Reduction in
Cholesterol Levels) randomized clinical trial demonstrated that
atorvastatin 80 mg daily(high-dose) begun at 1 to 6 months after the index event in
patients with noncardioembolic transient ischemic attack, and nonsevere
ischemic stroke was effective and safe for the prevention of recurrent
stroke and major cardiovascular events.1
(But shit, that high dose of statins is But in addition to their benefits for vascular prevention, might
statins also enhance neuroprotection or promote stroke recovery in the
acute setting?
Experimental studies in animal models have
reported that 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors (statins) reduce infarct volumes and stroke severity.2
Potentially beneficial nonlipid lowering (pleiotropic) effects of
statins include actions on the vascular wall (induction of angiogenesis,
upregulation of endothelial nitric oxide synthase), improved cerebral
blood flow, enhanced neural repair, antiplatelet, anti-inflammatory, and
antioxidant effects.2,3
Observational studies and meta-analyses have reported that statin use
either immediately before or shortly after stroke onset is associated
with improved functional outcome and lower fatality at early follow-up.4
However, no matter how tempting, inferences about therapeutic efficacy
cannot be made from observational studies because of selection bias and
other limitations. Randomized clinical trials are needed.
In this issue of Stroke, Yoshimura et al5
describe the results of the ASSORT trial (Administration of Statin on
Acute Ischemic Stroke Patient)—a prospective, open-label, blinded,
end-point assessed, randomized clinical trial, which compared the
efficacy of early (<24 hours) versus later (day 7) initiation of
statin therapy to improve functional outcome at 90 days in patients with
noncardioembolic stroke and dyslipidemia. Statin therapy included
low-dose atorvastatin, rosuvastatin, or pitavastatin, and outcome was
measured by shift across the modified Rankin Scale. Among 270 included
patients, no differences in modified Rankin Scale distribution, National
Institutes of Health Stroke Scale score, or early major cardiovascular
event recurrence were observed between groups. The adjusted common odds
ratio for functional outcome for the early statin group was 0.84 (95%
confidence interval, 0.53–1.3). This neutral result is consistent with
the recently reported neutral finding from the STARS trial (Stroke
Treatment With Acute Reperfusion and Simvastatin).6
Should
these results be interpreted as sufficient to close the case on the
question of whether acute statin therapy might improve functional
outcome after ischemic stroke? We think that such a conclusion may be
premature, at least for now. Although the authors should be commended
for conducting the trial, unfortunately some methodological limitations
may have contributed to the neutral findings in ASSORT. A major
limitation was a highly optimistic estimation of effect size (twice the
likelihood of improved modified Rankin Scale in statin-treated
patients), which likely led to an underpowered trial. Although the
effect size was estimated based on similar effect size observed in
observational studies, sufficient account was not given to the problem
that observational studies reporting acute statin benefits are highly
likely to be affected by prescribing bias, where patients with
less-severe stroke, healthier lifestyle, or fewer comorbid illnesses are
more likely to receive statin treatment. Other possible contributors to
the neutral results include the low doses and various statins used,
high number of patients with subcortical strokes (44% were lacunar),
milder-than-anticipated stroke severity of included patients, and lack
of quantitative outcome measures, such as motor strength and final
infarct volume.
An analysis of the SPARCL trial found
that among 492 patients with ischemic stroke outcomes at follow-up, a
strong statistical trend toward improved modified Rankin Scale at 90
days was evident in the group assigned atorvastatin 80 mg daily compared
with patients taking placebo (P=0.0647).7
Although this analysis was post hoc, and not clearly supported by
benefit measured by the National Institutes of Health Stroke Scale and
Barthel Index, these data are the largest to date in a randomized trial
of treatment with a standardized high-dose statin in the acute phase at
stroke onset. This intriguing signal from SPARCL, when combined with
supportive experimental and epidemiological data, suggests that more
randomized trials of acute statin therapy are needed.
Others
have evaluated the appropriate dose of statin therapy in acute
neuroprotection. In the Neu-START dose escalation study, a lovastatin
dose of 8 mg/kg per day for 3 days was identified as the maximum
tolerable dose.8
The follow-up Neu-START-2 phase 2b trial randomized 130 patients with
lovastatin 680 mg for 3 days starting within 24 hours poststroke versus
placebo (or lovastatin 80 mg for patients already taking statins before
stroke). The results of Neu-START-2 have not yet been published but are
expected soon (personal communication from Dr Elkind, Columbia
University).
Nevertheless, ASSORT and other trials have
provided reassuring data on the safety of acute statin treatment after
stroke. The design of new trials investigating this question should be
carefully considered. We support the STAIR recommendations (Stroke
Therapy Academic Industry Roundtable) for phase 2b trials of
neuroprotective agents.9
For statin trials, these might incorporate early standardized acute
statin treatment at the appropriate dose, with surrogate outcome
measures, such as infarct growth on brain imaging, to increase the
likelihood of detecting signals of efficacy. If phase 2 trials suggest
benefit, further phase 3 trials with adequate sample sizes to assess
functional measures should be conducted. Indeed, a properly designed
study testing high-dose acute statin therapy in moderate-to-severe
nonlacunar patients with stroke may still be warranted.
No comments:
Post a Comment